Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors
- 1 February 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (3), 959-962
- https://doi.org/10.1016/j.bmcl.2007.12.035
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase InhibitorCancer Research, 2007
- The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2007
- LapatinibNature Reviews Drug Discovery, 2007
- Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)European Journal of Cancer, 2007
- HER2-Positive Breast CancerDrugs, 2007
- 567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agentsEuropean Journal of Cancer Supplements, 2006
- Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer SignalingClinical Cancer Research, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- AEE788Cancer Research, 2004
- Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine KinaseCancer Research, 2004